Hurthle Cell Carcinoma Market Treatment Size to Reach USD 161.2 Million by 2035, Driven by Targeted Therapy and RAI-Refractory Treatment

According to DataM Intelligence, the global Hurthle cell Carcinoma market Treatment size is estimated at USD 90.0 million in 2025 and is forecast to reach USD 161.2 million by 2035, expanding at a CAGR of 6.0% during 2026-2035. The market is shifting toward more individualized care as oncocytic thyroid carcinoma becomes more clearly differentiated from conventional follicular thyroid cancer.
Surgery remains central, while radioactive iodine therapy is being used more selectively because of the disease's greater resistance to RAI. Targeted therapy is an important pharmaceutical segment for progressive or metastatic disease, with molecular profiling creating opportunities for RET- and NTRK-directed treatment in eligible patients. The report also identifies RAI-refractory disease, local treatment, redifferentiation approaches and emerging radioligand therapy as important areas of opportunity.
Get More About This Market Research Report: https://www.datamintelligence.com/research-report/hurthle-cell-carcinoma-market?akash

Recent Developments
• Eli Lilly - 2026: The current U.S. Retevmo label continues to cover RET fusion-positive advanced or metastatic thyroid cancer requiring systemic treatment when the disease is radioactive-iodine refractory if RAI is appropriate. The report identifies Eli Lilly as an important precision-oncology participant through this treatment pathway.
• Eisai - 2026: The report continues to position Eisai as a major systemic-treatment participant through Lenvima for progressive, radioactive-iodine-refractory differentiated thyroid cancer, including eligible oncocytic/Hurthle tumors.
• Exelixis - 2026: Exelixis remains positioned in the later-line systemic treatment pathway through Cabometyx for differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy in RAI-refractory or RAI-ineligible patients.

Mergers & Acquisitions
• New Hürthle-cell carcinoma clinical collaboration/trial: The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated a Phase 1/2 study of 177Lu-DOTA-EB-TATE for adults with metastatic, radioactive-iodine-nonresponsive oncocytic (Hürthle-cell) thyroid cancer. The study was scheduled to start in July 2026 and plans to enroll 18 patients. This represents a significant development toward targeted radioligand therapy for HCC.
• Major oncology acquisition with potential relevance to the broader thyroid-cancer treatment landscape: GSK agreed to acquire Nuvalent for $10.6 billion in June 2026, strengthening GSK's oncology portfolio with targeted cancer therapies. Although the acquisition is not Hürthle-cell-carcinoma-specific, it is a major 2026 oncology-market transaction that illustrates continued pharmaceutical investment in targeted cancer treatments.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/hurthle-cell-carcinoma-market?akash

Market Segmentation
By Stage
• Stage I
• Stage II
• Stage III
• Stage IV
Stage segmentation reflects different treatment requirements across localized and advanced disease. Stage IV accounts for the largest share of treatment revenue because metastatic patients may require systemic therapy, repeat imaging and additional local treatment.
By Treatment
• Surgery
• Radioactive Iodine Therapy
• Targeted Therapy
• Thyroid Hormone Therapy
• Immunotherapy
• Others
Surgery is the leading treatment segment in the report, while targeted therapy represents an important pharmaceutical component for progressive and metastatic disease. Radioactive iodine therapy remains relevant for selected patients, although treatment decisions increasingly depend on iodine avidity and recurrence risk.
By End Users
• Hospitals
• Ambulatory Surgical Centers
• Others
Hospitals represent the largest end-user segment, reflecting their role in thyroid surgery, radioactive iodine administration, molecular testing, metastatic-disease management and systemic treatment initiation.
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Regional segmentation shows substantial differences in treatment-market development. North America is the largest regional market, while Asia-Pacific is identified as the fastest-growing region through 2035.

Competitive Landscape
Top Five Key Players
• Eisai
• Exelixis
• Eli Lilly
• Bayer
• Roche/Genentech
Eisai: Eisai holds a central position in the market through Lenvima, which the report identifies as a major systemic treatment option for progressive radioactive-iodine-refractory differentiated thyroid cancer.
Exelixis: Exelixis participates through Cabometyx, providing a later-line treatment option for differentiated thyroid cancer following prior VEGFR-targeted therapy in appropriate RAI-refractory or RAI-ineligible patients.
Eli Lilly: Eli Lilly has a precision-oncology position through Retevmo for eligible RET fusion-positive advanced or metastatic thyroid cancer requiring systemic therapy when RAI is refractory if RAI is appropriate.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/hurthle-cell-carcinoma-market?akash

Regional Analysis
Europe is selected for comparison because it is neither the dominant region nor the fastest-growing region identified by DataM Intelligence. The region represents 27.3% of global Hurthle cell carcinoma treatment revenue in 2025. Germany is modeled as Europe's largest country market, followed by the UK, France, Italy and Spain.
The report associates Europe's market with established endocrine surgery and nuclear-medicine infrastructure, while reimbursement structures can affect uptake of expensive systemic therapies. The regional market is positioned behind North America and ahead of Asia-Pacific, Latin America, and the Middle East & Africa in the 2025 market structure.
North America dominates the market, accounting for 40.4% of global revenue. Asia-Pacific is the fastest-growing region through 2035. The report identifies Asia-Pacific's opportunity in the context of its large underlying thyroid-cancer population and expanding access to specialist treatment and genomic testing.

Conclusion
The Hurthle cell carcinoma market treatment share is moving toward a more differentiated treatment model in which surgery remains foundational but treatment after surgery depends increasingly on recurrence risk, disease distribution and radioactive iodine responsiveness. The report identifies a gradual shift away from an RAI-heavy approach toward selective RAI use, local disease control and systemic treatment for progressive disease.
The market is segmented across disease stage, treatment, end users and geography, with Stage IV disease generating substantial treatment revenue and hospitals remaining the principal treatment setting. North America leads the regional market, Europe holds a significant intermediate position, and Asia-Pacific is expected to grow fastest. Overall, the competitive environment remains connected to the broader differentiated thyroid cancer market, while disease-specific approaches for RAI-refractory Hurthle cell carcinoma provide the most distinct areas of emerging opportunity.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=hurthle-cell-carcinoma-market?akash

Industry Related Reports:
Refractive Vision Correction Market Share
The global Refractive Vision Correction Market reached USD 6.14 billion in 2025 and is expected to reach USD 8.53 billion by 2033, growing at a CAGR of 4.2% during 2026-2033. Rising demand for advanced vision correction procedures and increasing adoption of laser-based technologies are supporting market growth.
Get More Insights: https://www.datamintelligence.com/research-report/refractive-vision-correction-market?akash

Oral Obesity Drugs Market Growth
The global Oral Obesity Drugs Market reached USD 4.43 billion in 2025 and is expected to reach USD 58.91 billion by 2035, growing at a CAGR of 27.84% during 2026-2035. Growing adoption of oral GLP-1 therapies and other next-generation metabolic treatments is driving rapid market expansion.
Get More Insights: https://www.datamintelligence.com/research-report/oral-obesity-drugs-market?akash

Get More Japan Market Insights: https://www.datamintelligence.com/jp-market-research-report?akash

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.